Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | NCF1 | P14598 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 2/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10236411 | 1.00 | L3MBTL1 (0.37) | L3MBTL1ATMCYP2D6KCNH2HRH3 | |
| SCHEMBL179337 | 0.90 | NCF1 (0.40) | CYP2D6KCNH2HRH3NCF1CYP1A2 | |
| SCHEMBL12018058 | 0.84 | HTT (0.33) | L3MBTL1ATMCYP2D6KCNH2HRH3 | |
| SCHEMBL18923903 | 0.81 | ATM (0.49) | L3MBTL1ATMCYP2D6KCNH2HRH3 | |
| SCHEMBL2612760 | 0.81 | ATM (0.49) | L3MBTL1ATMCYP2D6KCNH2HRH3 | |
| SCHEMBL6784593 | 0.81 | ATM (0.49) | L3MBTL1ATMCYP2D6KCNH2HRH3 | |
| SCHEMBL25630748 | 0.80 | NCF1 (0.35) | L3MBTL1ATMNCF1 | |
| SCHEMBL15038219 | 0.79 | ATM (0.36) | L3MBTL1ATMHRH3NCF1ALDH1A1 | |
| SCHEMBL25949258 | 0.79 | ATM (0.36) | L3MBTL1ATMHRH3NCF1ALDH1A1 | |
| SCHEMBL24663753 | 0.78 | ATM (0.41) | L3MBTL1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11168093-B2 | Thienopyridine inhibitors of RIPK2 | CELGENE CORPORATION (US) | 2021-11-09 | — | — | US | disclosed |
| US-20200199148-A1 | THIENOPYRIDINE INHIBITORS OF RIPK2 | CELGENE CORPORATION | 2020-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200199148-A1 | THIENOPYRIDINE INHIBITORS OF RIPK2 | RIPK2, RIPK1, RIPK4 | L3MBTL1 3299/4885ATM 3190/4885CYP2D6 2953/4885 |
| US-11168093-B2 | Thienopyridine inhibitors of RIPK2 | RIPK2, RIPK1, RIPK4 | L3MBTL1 3299/4885ATM 3190/4885CYP2D6 2953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.